Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Durable multitransgene expression in vivo using systemic, nonviral DNA delivery. Science advances Handumrongkul, C. n., Ye, A. L., Chmura, S. A., Soroceanu, L. n., Mack, M. n., Ice, R. J., Thistle, R. n., Myers, M. n., Ursu, S. J., Liu, Y. n., Kashani-Sabet, M. n., Heath, T. D., Liggitt, D. n., Lewis, D. B., Debs, R. n. 2019; 5 (11): eaax0217

Abstract

Recombinant adeno-associated virus (AAV) vectors are transforming therapies for rare human monogenic deficiency diseases. However, adaptive immune responses to AAV and its limited DNA insert capacity, restrict their therapeutic potential. HEDGES (high-level extended duration gene expression system), a nonviral DNA- and liposome-based gene delivery platform, overcomes these limitations in immunocompetent mice. Specifically, one systemic HEDGES injection durably produces therapeutic levels of transgene-encoded human proteins, including FDA-approved cytokines and monoclonal antibodies, without detectable integration into genomic DNA. HEDGES also controls protein production duration from <3 weeks to >1.5 years, does not induce anti-vector immune responses, is reexpressed for prolonged periods following reinjection, and produces only transient minimal toxicity. HEDGES can produce extended therapeutic levels of multiple transgene-encoded therapeutic human proteins from DNA inserts >1.5-fold larger than AAV-based therapeutics, thus creating combinatorial interventions to effectively treat common polygenic diseases driven by multigenic abnormalities.

View details for DOI 10.1126/sciadv.aax0217

View details for PubMedID 31807699

View details for PubMedCentralID PMC6881169